SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.

Finally, the changes from baseline in commonly used surrogate cardiovascular biomarkers (hsCRP, IL-10, IL-6, TNF-α, and fibrinogen) between the FTC/TDF and 3TC/ABC arm in a subset of 159 subjects were not significant except a trend toward significance with fibrinogen ( P = .062) (Table 5 ), perhaps with a larger sample size it may have achieved significance.

also in 2,500 other papers